Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 160.09m |
Free float | 153.08m |
P/E (TTM) | -- |
Market cap | 1.29bn USD |
EPS (TTM) | -2.26 USD |
--
More ▼
Press releases
- Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
- Novavax to Participate in Jefferies London Healthcare Conference
- Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
- U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
- Åsa Manelius Named Managing Director of Novavax AB Site
- Åsa Manelius utnämnd till verkställande direktör för Novavax AB:s anläggning
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
- Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
More ▼